missing translation for 'onlineSavingsMsg'
Learn More
Learn More
HLA DRA Antibody (169-1B5.2), Alexa Fluor™ 750, Novus Biologicals™
Mouse Monoclonal Antibody
Marca: Novus Biologicals NBP2-47722AF750
Este artículo no se puede devolver.
Vea la política de devoluciones
Descripción
HLA DRA Monoclonal specifically detects HLA DRA in Human, Bovine, Feline samples. It is validated for Flow Cytometry, Immunocytochemistry/Immunofluorescence, Immunofluorescence.
Especificaciones
| HLA DRA | |
| Monoclonal | |
| Alexa Fluor 750 | |
| 50 mM sodium borate with 0.05% sodium azide | |
| HLA-DRA | |
| Human peripheral blood leukocytes (Uniprot: P01903) | |
| Primary | |
| This antibody detects a monomorphic general framework determinant of HLA-DR Class II antigen. It does not cross react with HLA-DP and HLA-DQ. HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36kDa alpha (heavy) chain and a 28kDa beta (light) chain. It is expressed on B-cells, activated T-cells, monocytes/macrophages, dendritic cells and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4+ T cells. It is an excellent histiocytic marker in paraffin sections producing intense cytoplasmic staining. True histiocytic neoplasms are similarly positive. HLA-DR antigens also occur on a variety of epithelial cells and their corresponding neoplastic counterparts. | |
| Store at 4°C in the dark. |
| Flow Cytometry, Immunofluorescence | |
| 169-1B5.2 | |
| Flow Cytometry, Immunofluorescence | |
| FLJ51114, histocompatibility antigen HLA-DR alpha, HLA class II histocompatibility antigen, DR alpha chain, HLA-DRA1, major histocompatibility complex, class II, DR alpha, MHC cell surface glycoprotein, MHC class II antigen DRA, MLRW | |
| Mouse | |
| 0.1 mL | |
| 3122 | |
| Human, Bovine, Feline | |
| IgG2b κ |
Corrección del contenido de un producto
Proporcione sus comentarios sobre el contenido del producto rellenando el siguiente formulario.
Título del producto
¿Detecta una oportunidad de mejora?Comparta una corrección de contenido